[go: up one dir, main page]

CY1116158T1 - Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 - Google Patents

Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3

Info

Publication number
CY1116158T1
CY1116158T1 CY20151100316T CY151100316T CY1116158T1 CY 1116158 T1 CY1116158 T1 CY 1116158T1 CY 20151100316 T CY20151100316 T CY 20151100316T CY 151100316 T CY151100316 T CY 151100316T CY 1116158 T1 CY1116158 T1 CY 1116158T1
Authority
CY
Cyprus
Prior art keywords
dihydroquinoline
carboxamides
oxo
substituted
thiooxy
Prior art date
Application number
CY20151100316T
Other languages
English (en)
Inventor
Sven Kühnert
Gregor Bahrenberg
Achim Kless
Wolfgang Schröder
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1116158T1 publication Critical patent/CY1116158T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε υποκατεστημένα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμίδια, σε φαρμακευτικές συνθέσεις που περιέχουν τις ενώσεις αυτές και επίσης στις ενώσεις αυτές για χρησιμοποίηση στη θεραπεία και/ή προφύλαξη πόνου και άλλων ασθενειών και/ή διαταραχών.
CY20151100316T 2010-08-27 2015-03-31 Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 CY1116158T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008920 2010-08-27
EP11754836.2A EP2609086B1 (en) 2010-08-27 2011-08-26 Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
CY1116158T1 true CY1116158T1 (el) 2017-02-08

Family

ID=43304979

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100316T CY1116158T1 (el) 2010-08-27 2015-03-31 Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3

Country Status (29)

Country Link
US (1) US8653102B2 (el)
EP (1) EP2609086B1 (el)
JP (1) JP5837934B2 (el)
KR (1) KR101983979B1 (el)
CN (1) CN103189357B (el)
AR (1) AR082731A1 (el)
AU (1) AU2011295408B2 (el)
BR (1) BR112013004690A2 (el)
CA (1) CA2809287C (el)
CL (1) CL2013000542A1 (el)
CO (1) CO6700825A2 (el)
CY (1) CY1116158T1 (el)
DK (1) DK2609086T3 (el)
EC (1) ECSP13012460A (el)
ES (1) ES2537615T3 (el)
HR (1) HRP20150520T1 (el)
HU (1) HUE024870T2 (el)
IL (1) IL223820A (el)
MX (1) MX342459B (el)
NZ (1) NZ608697A (el)
PE (1) PE20140214A1 (el)
PL (1) PL2609086T3 (el)
PT (1) PT2609086E (el)
RS (1) RS54002B1 (el)
RU (1) RU2581362C2 (el)
SI (1) SI2609086T1 (el)
TW (1) TWI552750B (el)
WO (1) WO2012025239A1 (el)
ZA (1) ZA201302265B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004562A2 (pt) * 2010-08-27 2016-09-06 Gruenenthal Gmbh 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
WO2014056620A1 (en) * 2012-10-11 2014-04-17 Grünenthal GmbH Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
CU24560B1 (es) * 2017-01-23 2021-12-08 Cadent Therapeutics Inc N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2482596A1 (fr) 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
DE3111934A1 (de) 1981-03-26 1982-10-07 Bayer Ag, 5090 Leverkusen Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung
FR2509728A1 (fr) 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
DE3210063A1 (de) 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DE3211934A1 (de) 1982-03-31 1983-10-13 Hoechst Ag, 6230 Frankfurt Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
FR2532939A1 (fr) 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
US5359365A (en) 1991-05-24 1994-10-25 Canon Kabushiki Kaisha Moving image processing method and apparatus
US6030983A (en) 1993-06-04 2000-02-29 Ball State University Lavendamycin analogs, quinoline-5,8-diones and methods of using them
US5525611A (en) 1993-06-04 1996-06-11 Behforouz; Mohammad Lavendamycin analogs and methods of making and using them
EP0634169B1 (en) 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (en) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Arylthioacetamide derivatives
JPH08337583A (ja) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
GB9807114D0 (en) 1998-04-02 1998-06-03 Smithkline Beecham Plc Novel process
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
WO2001010380A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
US6326385B1 (en) 1999-08-04 2001-12-04 Icagen, Inc. Methods for treating or preventing pain
CN100390148C (zh) 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
BR0116539A (pt) * 2000-12-28 2003-09-23 Shionogi & Co Derivados de piridona tendo uma atividade de ligação para o receptor 2 do tipo canabinóide
HUP0303841A2 (hu) 2001-02-20 2004-03-01 Bristol-Myers Squibb Company 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
JP2004526756A (ja) 2001-04-06 2004-09-02 スミスクライン ビーチャム コーポレーション ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤
US20040110947A1 (en) 2002-09-17 2004-06-10 Pharmacia Corporation Aromatic liver X-receptor modulators
MXPA05002983A (es) 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
CA2505195C (en) 2002-12-23 2012-07-10 Icagen, Inc. Quinazolinones as potassium channel modulators
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
EP1604983A4 (en) 2003-03-17 2008-06-25 Takeda Pharmaceutical Receptor Antagonists
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
AR048669A1 (es) 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
JP4054369B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
WO2006092143A1 (en) 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE602006007012D1 (de) 2005-07-20 2009-07-09 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
WO2007057447A1 (en) 2005-11-18 2007-05-24 Neurosearch A/S Novel quinazoline derivatives and their medical use
AU2006326662B2 (en) * 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
BRPI0709965C2 (pt) 2006-04-13 2011-12-20 Nupathe Inc formulações melhoradas de poliamina para a iontoforese do composto triptano
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
WO2007133637A2 (en) 2006-05-10 2007-11-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP2044018A1 (en) 2006-07-11 2009-04-08 Pfizer Japan, Inc. Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
CA2658190C (en) 2006-07-20 2013-01-29 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
US20100069380A1 (en) * 2006-09-22 2010-03-18 Soongyu Choi Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
JP2010512305A (ja) 2006-10-23 2010-04-22 ファイザー株式会社 置換フェニルメチルビシクロカルボキシアミド化合物
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
US9162984B2 (en) 2007-03-30 2015-10-20 University Of Rochester Small-molecule modulators of melanin expression
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
US8119656B2 (en) * 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010039534A2 (en) 2008-09-23 2010-04-08 Georgetown University Viral and fungal inhibitors
CA2739740A1 (en) 2008-10-24 2010-04-29 Gruenenthal Gmbh Substituted 4,5,6,7-tetrahydrothienopyridines as kcnq2/3 modulators for treating pain, epilepsy and urinary incontinence
US8367700B2 (en) 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
WO2010094644A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094645A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
MX2011008825A (es) 2009-03-10 2011-09-21 Gruenenthal Gmbh 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
BR112013004562A2 (pt) * 2010-08-27 2016-09-06 Gruenenthal Gmbh 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
US8445512B2 (en) 2010-08-27 2013-05-21 Gruenenthal Gmbh Substituted quinoline-3-carboxamides as KCNQ2/3 modulators

Also Published As

Publication number Publication date
RU2013113301A (ru) 2014-10-10
AU2011295408B2 (en) 2015-05-14
CO6700825A2 (es) 2013-06-28
HUE024870T2 (en) 2016-02-29
JP2013536213A (ja) 2013-09-19
RS54002B1 (sr) 2015-10-30
PE20140214A1 (es) 2014-02-19
KR20130095755A (ko) 2013-08-28
SI2609086T1 (sl) 2015-04-30
CL2013000542A1 (es) 2013-08-09
KR101983979B1 (ko) 2019-05-30
NZ608697A (en) 2014-07-25
TW201212917A (en) 2012-04-01
CN103189357A (zh) 2013-07-03
ES2537615T3 (es) 2015-06-10
PL2609086T3 (pl) 2015-07-31
TWI552750B (zh) 2016-10-11
ZA201302265B (en) 2021-05-26
AU2011295408A1 (en) 2013-04-11
IL223820A (en) 2016-08-31
MX342459B (es) 2016-09-29
EP2609086B1 (en) 2015-02-25
DK2609086T3 (da) 2015-03-30
ECSP13012460A (es) 2013-03-28
CA2809287C (en) 2018-05-22
US20120053206A1 (en) 2012-03-01
AR082731A1 (es) 2012-12-26
PT2609086E (pt) 2015-06-30
CA2809287A1 (en) 2012-03-01
BR112013004690A2 (pt) 2016-05-10
HK1185346A1 (en) 2014-02-14
RU2581362C2 (ru) 2016-04-20
EP2609086A1 (en) 2013-07-03
US8653102B2 (en) 2014-02-18
CN103189357B (zh) 2015-11-25
MX2013002119A (es) 2013-04-03
WO2012025239A1 (en) 2012-03-01
JP5837934B2 (ja) 2015-12-24
HRP20150520T1 (hr) 2015-07-03

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
UA110612C2 (uk) Похідні 1-аміно-2-циклопропілетилборонової кислоти
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
CY1118542T1 (el) Φθορομεθυλ-υποκατεστημενα καρβοξαμιδια πυρρολιου
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201391304A1 (ru) 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.